Overview
About
Who We Are
Executive Management
Board of Directors
Market Opportunities
News
Pipeline & Technology
Overview
Platforms
Oncology
Infectious Diseases
HIV
HBV
Advisors & Collaborators
Events & Presentations
Stock Info
Stock Quote
Stock Chart
Historical Stock Quote
Financials
SEC Filings
Governance
Governance Documents
Committee Composition
Board Diversity Matrix
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Skip to main content
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer
In silico detection for 12 additional cancers, including pancreatic
More than 2,600 proprietary biomarker panels
Rapidly expanding to other cancers and diseases
Innovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024
Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision,
in silico
drug discovery
Read more
GEDi Cube
Overview
About
Who We Are
Executive Management
Board of Directors
Market Opportunities
News
Pipeline & Technology
Overview
Platforms
Oncology
Infectious Diseases
HIV
HBV
Advisors & Collaborators
Events & Presentations
Stock Info
Stock Quote
Stock Chart
Historical Stock Quote
Financials
SEC Filings
Governance
Governance Documents
Committee Composition
Board Diversity Matrix
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Latest News
View all news
Latest Presentation